Abstract 5013
Background
Epithelioid sarcoma (ES) is a rare soft-tissue sarcoma (STS) (1%). Few recent studies describe pathological and clinical characteristics of ES. Little is known about management and outcomes of patients with localized diseases. The objectives are to study tumor characteristics and clinical management of ES patients with local and locally-advanced disease.
Methods
This is a retrospective study from the nation-wide French sarcoma network (NetSarc). From 2000 to 2016, patients with confirmed ES by expert pathologists, and with a localized disease were included. R2 were excluded.
Results
A total of 98 patients were analysed from 13 centres. Median age was 38 years (range 9-90) with male predominance (56%). The median size was 4 cm (0.3-72). Most common location was distal upper limb (40%). Pre-surgical biopsy was performed in 46% of patients. R0 resection was obtained for 64 patients (79%), R1 for 17 patients (21%). Margins revision surgery has been performed in 51% of patients. Limb-sparing was possible in 73% patients and amputation in 27%. Twenty-five patients (26%) received neoadjuvant treatments mainly chemotherapy with doxorubin-based regimen or isolated limb perfusion in 8 patients (10%). After surgery, 40 patients (43%) received adjuvant treatment, mainly radiotherapy (93%) and 20% received chemotherapy. After a median follow-up of 66.2 months (IC 95 48.4-74.7), 52% patients relapsed : locoregional relapse for 25 patients (52%), distant metastases for 35 patients (75%). The median disease-free-survival (DFS) was 54.5 months (IC95 33.7-105.6). Five-year overall survival (OS) rate was 71% (IC95 59-80). By univariate analyses, locally advanced disease and size larger than 5 cm were identified as a poor-prognosis factors for DFS and OS. R1 surgical margins were prognostic for OS. Proximal location, necrosis, mitosis index had no significant prognostic impact.
Conclusions
ES have a high rate of recurrence, particularly as locoregional relapse. Locally advanced disease, size larger than 5 cm, R1 surgical margins were identified as a poor-prognosis factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Perrin Christophe.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract